CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 246.38 AUD -0.09% Market Closed
Market Cap: 119.3B AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is 262.12 AUD. Compared to the current market price of 246.38 AUD, CSL Ltd is Undervalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
Base Case
262.12 AUD
Undervaluation 6%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
98
vs Industry
60
Median 3Y
6.6
Median 5Y
8.3
Industry
6.9
Forward
4.9
More Details
28.2
P/E
P/E
Price to Earnings
28.2
vs History
98
vs Industry
6
Median 3Y
38.1
Median 5Y
38.8
Industry
22.9
Forward
24.4
More Details
26.2
P/OCF
P/OCF
Price to OCF
26.2
vs History
96
vs Industry
7
Median 3Y
33.5
Median 5Y
33.3
Industry
19.7
More Details
54.7
P/FCFE
P/FCFE
Price to FCFE
54.7
vs History
60
vs Industry
4
Median 3Y
54.2
Median 5Y
70.6
Industry
23.5
More Details
4.2
P/B
P/B
Price to Book Value
4.2
vs History
98
vs Industry
23
Median 3Y
5.5
Median 5Y
6.3
Industry
2.5
More Details
5.6
EV/S
EV/S
Enterprise Value to Sales
5.6
vs History
98
vs Industry
47
Median 3Y
7.2
Median 5Y
8.7
Industry
7.4
Forward
5.4
More Details
10.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.8
vs History
98
vs Industry
36
Median 3Y
14
Median 5Y
15.8
Industry
9.1
More Details
17.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.4
vs History
98
vs Industry
8
Median 3Y
22.8
Median 5Y
24.7
Industry
3.8
Forward
16
More Details
21.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
21.7
vs History
98
vs Industry
7
Median 3Y
28.1
Median 5Y
29.4
Industry
3.8
Forward
18.8
More Details
28.9
EV/OCF
EV/OCF
Enterprise Value to OCF
28.9
vs History
82
vs Industry
5
Median 3Y
35.8
Median 5Y
35.6
Industry
4.9
More Details
45.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
45.7
vs History
88
vs Industry
3
Median 3Y
81.9
Median 5Y
78.5
Industry
3.5
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
98
vs Industry
43
Median 3Y
3.1
Median 5Y
5.3
Industry
4.6
More Details

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
119.3B AUD 5.1 28.2 17.4 21.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 170 874.7 -167 162 -202 987.9 -200 671.6
US
Abbvie Inc
NYSE:ABBV
323.7B USD 5.6 77.9 14.9 22
US
Amgen Inc
NASDAQ:AMGN
146.1B USD 4.3 24.6 13.5 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
133.7B USD 4.7 22.4 9.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112B USD 10.1 -113.3 24 25.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 003.1 -511.1 -556.6 -541.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
63.7B USD 4.5 14.1 12.7 14.3
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.7 -57.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.8B USD 16.1 -140.1 -625.8 -313.6
NL
argenx SE
XBRU:ARGX
31.4B EUR 16.2 42.5 -2 367.7 -1 587.4
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 197 542.1
5.1
7%
0.7
FR
Pharnext SCA
OTC:PNEXF
35 170 874.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 003.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
5%
0.9
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
29%
0.6
NL
argenx SE
XBRU:ARGX
16.2
39%
0.4
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 35
28.2
16%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 162 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.4
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -113.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -140.1 N/A N/A
NL
argenx SE
XBRU:ARGX
42.5
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 15.4
17.4
11%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 987.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -625.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 367.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 19.8
21.7
14%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 671.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -541.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 587.4 N/A N/A

See Also

Summary
CSL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CSL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CSL stock valuation using valuation multiples.
Wall Street Estimates
CSL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CSL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.